UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 986

Sortiert nach

The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510)

The Journal of pharmacology and experimental therapeutics, 2008-08, Vol.326 (2), p.672

2008

Link zum Volltext

Verfügbarkeit prüfen

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

Science translational medicine, 2016-11, Vol.8 (363), p.363ra150

2016

Link zum Volltext

Verfügbarkeit prüfen

The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors

Behavioural brain research, 2007-12, Vol.185 (1), p.32-42

2007

Link zum Volltext

Verfügbarkeit prüfen

Adenosine A_(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

Parkinson's disease, 2012-01, Vol.2012, p.591094-9

2012

Link zum Volltext

Verfügbarkeit prüfen

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

Experimental neurology, 2010-10, Vol.225 (2), p.384-390

2010

Link zum Volltext

Verfügbarkeit prüfen

Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders

Experimental neurology, 2010-10, Vol.225 (2), p.384

2010

Link zum Volltext

Verfügbarkeit prüfen

Updated Creutzfeldt–Jakob disease infection control guidelines: sifting facts from fiction

Medical journal of Australia, 2013-10, Vol.199 (8), p.535-536

Hodgson, Robert A

2013

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior

European journal of pharmacology, 2014-05, Vol.730, p.157-163

2014

Link zum Volltext

Verfügbarkeit prüfen

Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model

Pharmacology, biochemistry and behavior, 2014-03, Vol.118, p.36-45

2014

Link zum Volltext

Verfügbarkeit prüfen

Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: Sensitivity to anxiolytic and antidepressant drugs

Pharmacology, biochemistry and behavior, 2008, Vol.88 (3), p.341-348

2008

Link zum Volltext

Verfügbarkeit prüfen

Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

European journal of pharmacology, 2014-04, Vol.728, p.31-38

2014

Link zum Volltext

Verfügbarkeit prüfen

The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates

Psychopharmacologia, 2008-10, Vol.200 (3), p.393-401

2008

Link zum Volltext

Verfügbarkeit prüfen

The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): Comparison of efficacy and side effects across rodent species

European journal of pharmacology, 2011-07, Vol.661 (1), p.63-71

2011

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination

Pharmacology, biochemistry and behavior, 2011-04, Vol.98 (2), p.181-187

2011

Link zum Volltext

Verfügbarkeit prüfen

Tetrahydroquinoline sulfonamides as vasopressin 1b receptor anatgonists

Bioorganic & medicinal chemistry letters, 2009-11, Vol.19 (21), p.6018-6022

2009

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression

The Journal of pharmacology and experimental therapeutics, 2009-07, Vol.330 (1), p.294

2009

Link zum Volltext

Verfügbarkeit prüfen

Discovery of novel, potent BACE inhibitors with central activity for the treatment of Alzheimer's disease

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S532-S532

2010

Link zum Volltext

Verfügbarkeit prüfen

Effects of the selective adenosine A sub(2A) receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

European journal of pharmacology, 2014-04, Vol.728, p.31-38

2014

Link zum Volltext

Verfügbarkeit prüfen

The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]oct a ne-3-carboxamide (SCH 655842): Comparison of efficacy and side effects across rodent species

European journal of pharmacology, 2011-07, Vol.661 (1-3), p.63-71

2011

Link zum Volltext

Verfügbarkeit prüfen

Preladenant, a selective A sub(2A) receptor antagonist, is active in primate models of movement disorders

Experimental neurology, 2010-10, Vol.225 (2), p.384-390

2010

Link zum Volltext

Verfügbarkeit prüfen

The effects of adenosine A sub(2A) receptor antagonists on haloperidol-induced movement disorders in primates

Psychopharmacology, 2008-10, Vol.200 (3), p.393-401

2008

Link zum Volltext

Verfügbarkeit prüfen

Adenosine A2A Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

Parkinson's disease, 2011-12, Vol.2012

2011

Link zum Volltext

Verfügbarkeit prüfen

Preladenant, a selective A 2A receptor antagonist, is active in primate models of movement disorders

Experimental neurology, 2010, Vol.225 (2), p.384-390

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 986

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(847)
Mit Volltextzugriff
(907)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510)

The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

Discovery of the 3‑Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β‑Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors

Adenosine A_(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders

Updated Creutzfeldt–Jakob disease infection control guidelines: sifting facts from fiction

Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior

Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model

Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: Sensitivity to anxiolytic and antidepressant drugs

Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates

The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): Comparison of efficacy and side effects across rodent species

Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination

Tetrahydroquinoline sulfonamides as vasopressin 1b receptor anatgonists

Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression

Discovery of novel, potent BACE inhibitors with central activity for the treatment of Alzheimer's disease

Effects of the selective adenosine A sub(2A) receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]oct a ne-3-carboxamide (SCH 655842): Comparison of efficacy and side effects across rodent species

Preladenant, a selective A sub(2A) receptor antagonist, is active in primate models of movement disorders

The effects of adenosine A sub(2A) receptor antagonists on haloperidol-induced movement disorders in primates

Adenosine A2A Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease

Preladenant, a selective A 2A receptor antagonist, is active in primate models of movement disorders

Suchergebnisse filtern